Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6MZP7
UPID:
LIN54_HUMAN
Alternative names:
CXC domain-containing protein 1
Alternative UPACC:
Q6MZP7; Q32M68; Q32M69; Q6N071; Q76B60
Background:
Protein lin-54 homolog, also known as CXC domain-containing protein 1, plays a pivotal role in cell cycle regulation. It is a crucial component of the DREAM complex, which functions as a transcription activator or repressor depending on the cell cycle phase. This protein is essential for the repression of E2F target genes in G0 phase and activates G2/M genes necessary for mitosis in S phase. It specifically binds to the promoter of CDK1, recognizing the consensus motif 5'-TTYRAA-3'.
Therapeutic significance:
Understanding the role of Protein lin-54 homolog could open doors to potential therapeutic strategies.